Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Clenoliximab Chimeric Recombinant Rabbit Monoclonal Antibody (CE9.1 (Clenoliximab))
GREENER_CHOICE

Catalog No. PIMA547969
Change view
Click to view available options
Quantity:
200 μg
1 product options available for selection
Product selection table with 1 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
PIMA547969 200 μg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 1 options available.
1 options
Catalog No. PIMA547969 Supplier Invitrogen™ Supplier No. MA547969
Add to Cart
Add to Cart

Rabbit Recombinant Monoclonal Antibody

Specificity: The antibody binds to human CD4 with a Kd of 1.0 nM and an ED50 of 0.2 μg/mL.

Clenoliximab is a chimeric monoclonal antibody fromMacaca irusagainst CD4 which acts as an immunomodulator. It has investigated for the treatment of rheumatoid arthritis.
TRUSTED_SUSTAINABILITY

Specifications

Antigen Clenoliximab Chimeric
Applications ELISA, Flow Cytometry, Inhibition Assays, Immunohistochemistry, Surface Plasmon Resonance
Classification Recombinant Monoclonal
Clone CE9.1 (Clenoliximab)
Concentration 1 mg/mL
Conjugate Unconjugated
Formulation PBS with 0.02% ProClin 300
Gene Alias 4PE; IDEC-151
Host Species Rabbit
Immunogen Domain 1 of human CD4.
Purification Method Protein A
Quantity 200 μg
Regulatory Status RUO
Primary or Secondary Primary
Target Species Chimpanzee, Human
Content And Storage Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Product Type Antibody
Form Liquid
Isotype IgG λ
Show More Show Less
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.